U.S. Market Opens for Slovenian Pharmaceutical

Ljubljana, 26 November - Slovenia's pharmaceutical Lek received final approval from the U.S. Food and Drug Administration (FDA) for an immediate start of distribution and sales on the U.S. market of Ko-amoksiklav, an antibiotic for treatment of broad-spectrum bacterial infections, the Ljubljana-based company said Tuesday.